![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, December 13, 2019 9:36:02 AM
1. Did second run take longer, if so, will this affect anything?
2. Is there a fee for IND? if so how do you plan on paying the fee?
3. Do you plan on selling shares below the retail value? if so at what
price.
4. Estimate on how many shares per month you plan on selling to meet
our budget needs.
5. Estimate time to do the final testing?
6. Are you currently negotiating with another company for potential partnership?
7. Where are we with the final piece of the first and second runs test?
8. if we get a partner will pmcb salaries continue?
9. what are our plans if the tests fail?
10. Why aren’t you selling shares on the daily market for 3 cents instead of discounting them to one sixth of that price and allowing those buyers to immediately sell them for a 600% gain on the daily market? Isn’t this a massive loss to the company?
11. Have any of the buyers of the discounted shares or their companies or their associates been investigated by the sec and found guilty of any offence?
12. Why is the cfo being paid above industry standards and why does the company need a full time cfo?
13. Name the foundations you have contacted about funding and give the precise reasons they have not funded us?
14. Why were board members allowed to make decisions about the company and in particular the compensation of the ceo and cfo when they hadn’t been properly elected?
15. How is it possible that our ceo as our legal counsel didn’t do anything about this?
16. Why hasn’t there been an annual shareholder meeting when the by laws require one each year?
17. Why didn’t the ceo call annual shareholder meetings as required by the bylaws?
18. Has the board given the poison pill share/s to anyone yet?
19. Can you provide the minutes of all the company board meetings held so far and make them available online ?
20. Why aren’t you recording ccs for later reference?
21. As the salary increases granted after the pre ind meeting with the fda were not granted according to the by laws because the committee members were not elected by shareholders. Will those who obtained increases refund their salaries and shares to the company?
22. Please update us on the recent meeting you had in Chicago?
23. Please say if ndas have been signed with any listed companies?
24. Why no live Q&A?
Recent PMCB News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:05:04 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/30/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:40:20 PM
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease • Business Wire • 05/21/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/21/2023 09:04:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/18/2023 10:04:06 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 09/15/2023 09:00:03 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/12/2023 01:56:25 AM
FEATURED ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM